collection
MENU ▼
Read by QxMD icon Read
search

Diabetes

shared collection
93 papers 25 to 100 followers Related to managing patients with diabetes
By Michael Kelly Assistant Professor
https://www.readbyqxmd.com/read/29144162/association-between-metformin-adherence-and-all-cause-mortality-among-new-users-of-metformin-a-nested-case-control-study
#1
Patrice Simard, Nancy Presse, Louise Roy, Marc Dorais, Brian White-Guay, Agnès Räkel, Sylvie Perreault
BACKGROUND: Metformin presents better survival rates than other oral antidiabetics in the treatment of type 2 diabetes. However, these benefits may be dampened by inadequate treatment adherence. OBJECTIVE: We aimed to investigate the relationship between adherence level to metformin therapy and all-cause mortality over 10 years in incident metformin users. METHODS: A nested case-control study was conducted using a large cohort of beneficiaries of the Quebec public drug insurance plan, aged 45 to 85 years, who initiated metformin between 2000 and 2009...
November 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/29114778/long-term-sustainability-of-diabetes-prevention-approaches-a-systematic-review-and-meta-analysis-of-randomized-clinical-trials
#2
J Sonya Haw, Karla I Galaviz, Audrey N Straus, Alysse J Kowalski, Matthew J Magee, Mary Beth Weber, Jingkai Wei, K M Venkat Narayan, Mohammed K Ali
Importance: Diabetes prevention is imperative to slow worldwide growth of diabetes-related morbidity and mortality. Yet the long-term efficacy of prevention strategies remains unknown. Objective: To estimate aggregate long-term effects of different diabetes prevention strategies on diabetes incidence. Data Sources: Systematic searches of MEDLINE, EMBASE, Cochrane Library, and Web of Science databases. The initial search was conducted on January 14, 2014, and was updated on February 20, 2015...
November 6, 2017: JAMA Internal Medicine
https://www.readbyqxmd.com/read/29138275/enhanced-predictive-capability-of-a-1-hour-oral-glucose-tolerance-test-a-prospective-population-based-cohort-study
#3
Manan Pareek, Deepak L Bhatt, Mette L Nielsen, Ram Jagannathan, Karl-Fredrik Eriksson, Peter M Nilsson, Michael Bergman, Michael H Olsen
OBJECTIVE: To examine whether the 1-h blood glucose measurement would be a more suitable screening tool for assessing the risk of diabetes and its complications than the 2-h measurement. RESEARCH DESIGN AND METHODS: We conducted a prospective population-based cohort study of 4,867 men, randomly selected from prespecified birth cohorts between 1921 and 1949, who underwent an oral glucose tolerance test with blood glucose measurements at 0, 1, and 2 h. Subjects were followed for up to 39 years, with registry-based recording of events...
November 14, 2017: Diabetes Care
https://www.readbyqxmd.com/read/29079715/changes-in-albuminuria-and-the-risk-of-major-clinical-outcomes-in-diabetes-results-from-advance-on
#4
Min Jun, Toshiaki Ohkuma, Sophia Zoungas, Stephen Colagiuri, Giuseppe Mancia, Michel Marre, David Matthews, Neil Poulter, Bryan Williams, Anthony Rodgers, Vlado Perkovic, John Chalmers, Mark Woodward
OBJECTIVE: To assess the association between 2-year changes in urine albumin-to-creatinine ratio (UACR) and the risk of clinical outcomes in type 2 diabetes. RESEARCH DESIGN AND METHODS: We analyzed data from 8,766 participants in the ADVANCE-ON study. Change in UACR was calculated from UACR measurements 2 years apart, classified into three groups: decrease in UACR of ≥30%, minor change, and increase in UACR of ≥30%. By analyzing changes from baseline UACR groups, categorized into thirds, we repeated these analyses accounting for regression to the mean (RtM)...
October 27, 2017: Diabetes Care
https://www.readbyqxmd.com/read/28948839/effective-interventions-for-diabetes-patients-by-community-pharmacists-a-meta-analysis-of-pharmaceutical-care-components
#5
Maira Anna Deters, Anna Laven, Ana Castejon, William R Doucette, Lisiane Slveira Ev, Ines Krass, Els Mehuys, Emina Obarcanin, Holger Schwender, Stephanie Laeer
OBJECTIVE: To evaluate randomized controlled trials (RCTs) that included interventions provided by community pharmacists for patients with type 1 and 2 diabetes, the analysis of each component of the intervention(s), and the description of the training that the pharmacists received. DATA SOURCES: The literature research was conducted in PubMed and in the Cochrane Central Register of Controlled Trials (January 2000 to April 2016) for RCTs with interventions provided by community pharmacists for patients with diabetes...
September 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28899219/adjunctive-treatments-for-type-1-diabetes
#6
David M Nathan
The proliferation of new drug treatments for type 2 diabetes in the United States in the past 15 years, with more than 17 drugs approved in six new classes of antidiabetic drugs, has been promoted by several factors. First, the recognition of the importance of intensive glycemic control to reduce..
September 13, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28912305/effects-of-liraglutide-on-weight-loss-fat-distribution-and-%C3%AE-cell-function-in-obese-subjects-with-prediabetes-or-early-type-2-diabetes
#7
Francesca Santilli, Paola G Simeone, Maria T Guagnano, Marika Leo, Marica T Maccarone, Augusto Di Castelnuovo, Cristina Sborgia, Riccardo C Bonadonna, Ermanno Angelucci, Virginia Federico, Stefano Cianfarani, Lamberto Manzoli, Giovanni Davì, Armando Tartaro, Agostino Consoli
OBJECTIVE: Obesity is associated with an increased risk of type 2 diabetes and cardiovascular complications. The risk depends significantly on adipose tissue distribution. Liraglutide, a glucagon-like peptide 1 analog, is associated with weight loss, improved glycemic control, and reduced cardiovascular risk. We determined whether an equal degree of weight loss by liraglutide or lifestyle changes has a different impact on subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) in obese subjects with prediabetes or early type 2 diabetes...
November 2017: Diabetes Care
https://www.readbyqxmd.com/read/28892816/treatment-of-type-1-diabetes-synopsis-of-the-2017-american-diabetes-association-standards-of-medical-care-in-diabetes
#8
James J Chamberlain, Rita Rastogi Kalyani, Sandra Leal, Andrew S Rhinehart, Jay H Shubrook, Neil Skolnik, William H Herman
Description: The American Diabetes Association (ADA) annually updates Standards of Medical Care in Diabetes to provide clinicians, patients, researchers, payers, and other interested parties with evidence-based recommendations for the diagnosis and management of patients with diabetes. Methods: For the 2017 Standards of Care, the ADA Professional Practice Committee did MEDLINE searches from 1 January 2016 to November 2016 to add, clarify, or revise recommendations on the basis of new evidence...
October 3, 2017: Annals of Internal Medicine
https://www.readbyqxmd.com/read/28757642/mexican-origin-male-perspectives-of-diet-related-behaviors-associated-with-weight-management
#9
L A Valdez, A Amezquita, S P Hooker, D O Garcia
BACKGROUND: Prevalence rates of obesity and related diseases are quickly reaching epidemic proportions among Hispanic males in the United States. Hispanic males suffer from the highest prevalence of obesity-related diseases when compared to all other racial/ethnic groups. Despite evidence showing that weight loss can significantly reduce the risk of obesity-related health implications, literature informing best practices to engage Hispanic males in weight management programs is scarce...
July 31, 2017: International Journal of Obesity: Journal of the International Association for the Study of Obesity
https://www.readbyqxmd.com/read/28830958/diabetes-and-hypertension-a-position-statement-by-the-american-diabetes-association
#10
REVIEW
Ian H de Boer, Sripal Bangalore, Athanase Benetos, Andrew M Davis, Erin D Michos, Paul Muntner, Peter Rossing, Sophia Zoungas, George Bakris
No abstract text is available yet for this article.
September 2017: Diabetes Care
https://www.readbyqxmd.com/read/28776086/the-mechanisms-of-action-of-metformin
#11
REVIEW
Graham Rena, D Grahame Hardie, Ewan R Pearson
Metformin is a widely-used drug that results in clear benefits in relation to glucose metabolism and diabetes-related complications. The mechanisms underlying these benefits are complex and still not fully understood. Physiologically, metformin has been shown to reduce hepatic glucose production, yet not all of its effects can be explained by this mechanism and there is increasing evidence of a key role for the gut. At the molecular level the findings vary depending on the doses of metformin used and duration of treatment, with clear differences between acute and chronic administration...
August 3, 2017: Diabetologia
https://www.readbyqxmd.com/read/28828487/continuous-glucose-monitoring-versus-usual-care-in-patients-with-type-2-diabetes-receiving-multiple-daily-insulin-injections-a-randomized-trial
#12
RANDOMIZED CONTROLLED TRIAL
Roy W Beck, Tonya D Riddlesworth, Katrina Ruedy, Andrew Ahmann, Stacie Haller, Davida Kruger, Janet B McGill, William Polonsky, David Price, Stephen Aronoff, Ronnie Aronson, Elena Toschi, Craig Kollman, Richard Bergenstal
Background: Continuous glucose monitoring (CGM), which studies have shown is beneficial for adults with type 1 diabetes, has not been well-evaluated in those with type 2 diabetes receiving insulin. Objective: To determine the effectiveness of CGM in adults with type 2 diabetes receiving multiple daily injections of insulin. Design: Randomized clinical trial. (The protocol also included a type 1 diabetes cohort in a parallel trial and subsequent second trial...
September 19, 2017: Annals of Internal Medicine
https://www.readbyqxmd.com/read/28076259/almond-appetizer-effect-on-glucose-tolerance-test-gtt-results
#13
Michael A Crouch, Robert T Slater
BACKGROUND: The extent to which glucose intolerance can be acutely improved with dietary modification is unclear. The purpose of this study was to test the effect of ingesting a low-calorie almond preload ("appetizer") 30 minutes before oral glucose tolerance testing in glucose-intolerant individuals without diabetes. METHODS: Twenty adults with prediabetes or isolated 1-hour glucose ≥160 mg/dL underwent 2 fasting oral glucose tolerance tests (GTTs)-1 standard GTT and 1 GTT 30 minutes after eating a half ounce (12) of dry-roasted almonds...
November 2016: Journal of the American Board of Family Medicine: JABFM
https://www.readbyqxmd.com/read/28801475/understanding-the-gap-between-efficacy-in-randomized-controlled-trials-and-effectiveness-in-real-world-use-of-glp-1-ra-and-dpp-4-therapies-in-patients-with-type-2-diabetes
#14
Ginger S Carls, Edward Tuttle, Ruo-Ding Tan, Johnny Huynh, John Yee, Steven V Edelman, William H Polonsky
OBJECTIVE: The objective of this study was to estimate and explain the gap between clinical efficacy and real-world (RW) effectiveness of type 2 diabetes medications. RESEARCH DESIGN AND METHODS: This mixed-methods quasi-experimental study used retrospective claims (Optum/Humedica) to compare the change in HbA1c of RW patients with type 2 diabetes 12 months after starting a glucagon-like peptide 1 receptor agonist (GLP-1 RA) or dipeptidyl peptidase 4 (DPP-4) inhibitor with published findings from randomized controlled trials (RCTs) evaluating these drugs...
November 2017: Diabetes Care
https://www.readbyqxmd.com/read/28799414/the-clinical-use-of-a-fixed-dose-combination-of-insulin-degludec-and-liraglutide-xultophy-100-3-6-for-the-treatment-of-type-2-diabetes
#15
Kira Harris, Kimberly Lovin Nealy
OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, and safety of the fixed-dose combination of insulin degludec and the glucagon-like peptide-I receptor agonist (GLP-1 RA), liraglutide (IDegLira) in the treatment of type 2 diabetes mellitus (T2DM). DATA SOURCES: A PubMed and MEDLINE search (1966 to July 2017) of the keywords insulin degludec, liraglutide, and type 2 diabetes mellitus was conducted. References were reviewed to identify additional citations...
August 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28754780/2017-national-standards-for-diabetes-self-management-education-and-support
#16
REVIEW
Joni Beck, Deborah A Greenwood, Lori Blanton, Sandra T Bollinger, Marcene K Butcher, Jo Ellen Condon, Marjorie Cypress, Priscilla Faulkner, Amy Hess Fischl, Theresa Francis, Leslie E Kolb, Jodi M Lavin-Tompkins, Janice MacLeod, Melinda Maryniuk, Carolé Mensing, Eric A Orzeck, David D Pope, Jodi L Pulizzi, Ardis A Reed, Andrew S Rhinehart, Linda Siminerio, Jing Wang
No abstract text is available yet for this article.
October 2017: Diabetes Care
https://www.readbyqxmd.com/read/28751548/comparison-of-ipragliflozin-and-pioglitazone-effects-on-nonalcoholic-fatty-liver-disease-in-patients-with-type-2-diabetes-a-randomized-24-week-open-label-active-controlled-trial
#17
Daisuke Ito, Satoshi Shimizu, Kazuyuki Inoue, Daigo Saito, Morifumi Yanagisawa, Kouichi Inukai, Yuji Akiyama, Yoshihiro Morimoto, Mitsuhiko Noda, Akira Shimada
OBJECTIVE: To compare the efficacy of ipragliflozin versus pioglitazone in patients with type 2 diabetes complicated by nonalcoholic fatty liver disease (NAFLD). RESEARCH DESIGN AND METHODS: In this open-label, randomized, active-controlled trial, we randomly assigned 66 patients with type 2 diabetes and NAFLD to receive ipragliflozin 50 mg (n = 32) or pioglitazone 15-30 mg (n = 34) orally once daily. The primary outcome was a change from baseline in the liver-to-spleen attenuation ratio (L/S ratio) on computed tomography at week 24...
October 2017: Diabetes Care
https://www.readbyqxmd.com/read/28733374/the-fallacy-of-average-how-using-hba1c-alone-to-assess-glycemic-control-can-be-misleading
#18
Roy W Beck, Crystal G Connor, Deborah M Mullen, David M Wesley, Richard M Bergenstal
HbA1c is a valuable metric for comparing treatment groups in a randomized trial, for assessing glycemic trends in a population over time, or for cross-sectional comparisons of glycemic control in different populations. However, what is not widely appreciated is that HbA1c may not be a good indicator of an individual patient's glycemic control because of the wide range of mean glucose concentrations and glucose profiles that can be associated with a given HbA1c level. To illustrate this point, we plotted mean glucose measured with continuous glucose monitoring (CGM) versus central laboratory-measured HbA1c in 387 participants in three randomized trials, showing that not infrequently HbA1c may underestimate or overestimate mean glucose, sometimes substantially...
August 2017: Diabetes Care
https://www.readbyqxmd.com/read/28733377/is-it-time-to-change-the-type-2-diabetes-treatment-paradigm-yes-glp-1-ras-should-replace-metformin-in-the-type-2-diabetes-algorithm
#19
Muhammad Abdul-Ghani, Ralph A DeFronzo
Most treatment guidelines, including those from the American Diabetes Association/European Association for the Study of Diabetes and the International Diabetes Federation, suggest metformin be used as the first-line therapy after diet and exercise. This recommendation is based on the considerable body of evidence that has accumulated over the last 30 years, but it is also supported on clinical grounds based on metformin's affordability and tolerability. As such, metformin is the most commonly used oral antihyperglycemic agent in the U...
August 2017: Diabetes Care
https://www.readbyqxmd.com/read/28327588/pharmacological-inhibition-of-adipose-triglyceride-lipase-corrects-high-fat-diet-induced-insulin-resistance-and-hepatosteatosis-in-mice
#20
Martina Schweiger, Matthias Romauch, Renate Schreiber, Gernot F Grabner, Sabrina Hütter, Petra Kotzbeck, Pia Benedikt, Thomas O Eichmann, Sohsuke Yamada, Oskar Knittelfelder, Clemens Diwoky, Carina Doler, Nicole Mayer, Werner De Cecco, Rolf Breinbauer, Robert Zimmermann, Rudolf Zechner
Elevated circulating fatty acids (FAs) contribute to the development of obesity-associated metabolic complications such as insulin resistance (IR) and non-alcoholic fatty liver disease (NAFLD). Hence, reducing adipose tissue lipolysis to diminish the mobilization of FAs and lower their respective plasma concentrations represents a potential treatment strategy to counteract obesity-associated disorders. Here we show that specific inhibition of adipose triglyceride lipase (Atgl) with the chemical inhibitor, Atglistatin, effectively reduces adipose tissue lipolysis, weight gain, IR and NAFLD in mice fed a high-fat diet...
March 22, 2017: Nature Communications
label_collection
label_collection
7141
1
2
2017-07-19 15:39:16
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"